Dennis Ding
Stock Analyst at Jefferies
(4.09)
# 1,650
Out of 5,000 analysts
92
Total ratings
58.6%
Success rate
10.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Reiterated: Buy | $42 → $52 | $36.13 | +43.92% | 18 | Sep 8, 2026 | |
| TARS Tarsus Pharmaceuticals | Reiterated: Buy | $105 | $75.96 | +38.23% | 1 | Sep 8, 2026 | |
| TEVA Teva Pharmaceutical Industries | Reiterated: Buy | $40 | $40.22 | -0.55% | 6 | Sep 3, 2026 | |
| KARD Kardigan | Initiated Coverage: Buy | $40 | $14.39 | +177.97% | 1 | Jul 13, 2026 | |
| TSX: APTX Apotex Health Corp. | Initiated Coverage: Buy | $40.00 | $33.05 | +21.03% | 1 | Jul 6, 2026 | |
| ARDX Ardelyx | Reiterated: Buy | $15 | $3.45 | +334.78% | 7 | Jun 26, 2026 | |
| RYTM Rhythm Pharmaceuticals | Reiterated: Buy | $125 | $98.31 | +27.15% | 10 | Jun 15, 2026 | |
| SGP SpyGlass Pharma | Reiterated: Buy | $62 | $27.65 | +124.23% | 4 | May 19, 2026 | |
| AMPH Amphastar Pharmaceuticals | Downgraded: Hold | $22 | $26.27 | -16.25% | 1 | Apr 21, 2026 | |
| OLMA Olema Pharmaceuticals | Initiated Coverage: Buy | $40 | $9.04 | +342.48% | 1 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $4.88 | +43.44% | 4 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $15 → $26 | $26.59 | n/a | 5 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $45 | $22.74 | n/a | 14 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $20 → $18 | $34.00 | n/a | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 | $2.10 | n/a | 1 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $35 | $23.66 | n/a | 1 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $8 → $6 | $3.89 | n/a | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 | $2.51 | n/a | 2 | Jul 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $2,275 → $70 | $14.74 | n/a | 4 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $1.06 | n/a | 3 | Jul 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $35 → $22 | $118.51 | n/a | 4 | Feb 14, 2023 |
Roivant Sciences
Sep 8, 2026
Reiterated: Buy
Price Target: $42 → $52
Current: $36.13
Upside: +43.92%
Tarsus Pharmaceuticals
Sep 8, 2026
Reiterated: Buy
Price Target: $105
Current: $75.96
Upside: +38.23%
Teva Pharmaceutical Industries
Sep 3, 2026
Reiterated: Buy
Price Target: $40
Current: $40.22
Upside: -0.55%
Kardigan
Jul 13, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $14.39
Upside: +177.97%
Apotex Health Corp.
Jul 6, 2026
Initiated Coverage: Buy
Price Target: $40.00
Current: $33.05
Upside: +21.03%
Ardelyx
Jun 26, 2026
Reiterated: Buy
Price Target: $15
Current: $3.45
Upside: +334.78%
Rhythm Pharmaceuticals
Jun 15, 2026
Reiterated: Buy
Price Target: $125
Current: $98.31
Upside: +27.15%
SpyGlass Pharma
May 19, 2026
Reiterated: Buy
Price Target: $62
Current: $27.65
Upside: +124.23%
Amphastar Pharmaceuticals
Apr 21, 2026
Downgraded: Hold
Price Target: $22
Current: $26.27
Upside: -16.25%
Olema Pharmaceuticals
Mar 19, 2026
Initiated Coverage: Buy
Price Target: $40
Current: $9.04
Upside: +342.48%
Dec 11, 2025
Reiterated: Buy
Price Target: $7
Current: $4.88
Upside: +43.44%
Sep 3, 2025
Reiterated: Hold
Price Target: $15 → $26
Current: $26.59
Upside: n/a
Jun 11, 2025
Reiterated: Buy
Price Target: $45
Current: $22.74
Upside: n/a
May 29, 2025
Reiterated: Hold
Price Target: $20 → $18
Current: $34.00
Upside: n/a
Nov 7, 2024
Initiated Coverage: Buy
Price Target: $8
Current: $2.10
Upside: n/a
Sep 19, 2024
Upgraded: Buy
Price Target: $35
Current: $23.66
Upside: n/a
Sep 3, 2024
Reiterated: Hold
Price Target: $8 → $6
Current: $3.89
Upside: n/a
Jul 17, 2024
Reiterated: Hold
Price Target: $1
Current: $2.51
Upside: n/a
Jun 17, 2024
Downgraded: Hold
Price Target: $2,275 → $70
Current: $14.74
Upside: n/a
Jul 13, 2023
Reiterated: Buy
Price Target: $18
Current: $1.06
Upside: n/a
Feb 14, 2023
Rated: Hold
Price Target: $35 → $22
Current: $118.51
Upside: n/a